i2o Pipeline

i2o Therapeutics is developing proprietary products for cardio-metabolic diseases and adjacent indications.

i2o’s medicines combined with differentiated delivery platforms hold the promise of raising the current standard of care

Product

Preclinical

Clinical

Filed (with US FDA)

FDA Approval

Indication(s)

ITCA 650 (GLP-1 RA, Exenatide, Twice yearly)

T2D

i2o-105s (LA GLP-1 RA)

T2D, Obesity, NASH

i2o-107 (LA Amylin)

T2D, Obesity, NASH

i2o-110 (Dual agonist combination)

T2D, Obesity, NASH

i2o-120 (LA PYY)

T2D, Obesity, NASH

i2o-130 (LA Glucagon)

T2D, Obesity, NASH